Analysis: Cupid Limited

What does Cupid Limited do?

• Cupid Limited is a manufacturer and exporter of male/female condoms, water-based lubricants, and in-vitro diagnostics (IVD) kits, headquartered in Nashik, Maharashtra.
• First Indian company to achieve WHO/UNfpa prequalification for both male and female condoms, with global exports to 110+ countries.
• Transitioned from a B2B-focused entity to a multi-category consumer wellness company with a B2C FMCG expansion in FY24.

• Core products: Male/female condoms, personal lubricants, and IVD kits (e.g., pregnancy, malaria, and STI tests).
• B2B institutional sales to governments agencies, UNFPA, NGOs, and global health programs.
• B2C FMCG expansion in India with personal care products (deodorants, perfumes, menstrual cups, and hair care).

Growth thesis

Cupid Ltd is a manufacturer of male/female condoms, lubricants, and in vitro diagnostics (IVD) kits, with 75% revenue from male condoms and 19-23% from female condoms. Key growth drivers include Rs 50–60 cr capex to expand male condom capacity to 1 bn units/year and female condoms to 100 m units, plus Rs 385 cr earmarked for acquiring non-latex condom assets in Asia. The business aims to double revenue to Rs 400 cr by FY27 through FDA approval of female condoms (H1-26 target) and scaling IVD kits to Rs 50–100 cr by FY26. Risks include delayed FDA timelines (clinical trials ongoing), order-book volatility (Rs 80 cr visible but South Africa/Brazil/UNFPA delays recur), and margin compression if IVD scale-up lags WHO/CE certifications. Management underdelivered on female-condom sales (Rs 22 cr vs. Rs 32 cr FY24 guidance) and US-FDA entry, though capex execution and land acquisition remain on track.

Why is Cupid Limited stock rising?

• Strategic acquisition using ₹385Cr fundraise to add non-latex condom manufacturing (polyisoprene, polyurethane) and expedite IVD approvals
• Adding 300M units male condom capacity via new dipping lines by end of 2024
• B2C retail entry in India with product bundling (condoms + deodorant sprays) targeting 1,000+ outlets
• USFDA approval for female condoms expected by FY26
• Improving cash conversion cycle by reducing inventory days by 40-45 days

Research report

companyname: Cupid Limited ticker: CUPID sector: Healthcare – Sexual Wellness & Diagnostics Cupid Limited is an Indian manufacturer and global exporter of male condoms, female condoms, water-based lubricants, and in-vitro diagnostic (IVD) kits. Founded in 1993 and headquartered in Sinnar, Nashik, the company has over three decades of manufacturing experience. Its facility spans over 100,000 sq. ft. and had ~206 permanent employees as of FY25. Cupid exports to over 110 countries, with ~48% of FY...

Catalysts

capex, margin expansion, regulatory approval, acquisition inorganic

Growth guidance

~$400 crores revenue target post expansion; EBITDA >$100 crores

Management consistency

mixed